ERCC2 and lung cancer: Patients with homozygous mutant variants (Gln/Gln) of XPD were found significantly associated with a 3.6 fold increased risk of lung cancer compared to the control (OR=3.58; 95% CI=1.58-8.09; p=0.002), whereas no significant association was found with heterozygous mutant variants (Lys/Gln) (Table 2).